Management of Chronic Liver Disease

Introduction to Chronic Liver Disease Management

• The American Association for the Study of Liver Diseases recommends identifying and treating the specific underlying cause of chronic liver disease to prevent progression to cirrhosis and hepatocellular carcinoma 1, 2

Viral Hepatitis Management

• For chronic hepatitis B, the American Association for the Study of Liver Diseases recommends using first-line agents entecavir, tenofovir, or peginterferon alfa-2a in patients with elevated ALT and HBV DNA ≥2000 IU/mL 1
• The American Association for the Study of Liver Diseases recommends that all cirrhotic patients with detectable HBV DNA require treatment regardless of ALT levels 1
• The American Association for the Study of Liver Diseases suggests monitoring HBV DNA and ALT every 3-6 months during therapy, and assessing for virologic breakthrough and renal function in patients on nucleos(t)ide analogues 1
• For chronic hepatitis C, the American Association for the Study of Liver Diseases recommends using direct-acting antivirals (DAAs) to achieve high cure rates in all eligible patients 1
• The American Association for the Study of Liver Diseases states that sustained viral suppression for HBV and sustained viral response for HCV prevent cirrhosis progression and reduce (but do not eliminate) HCC risk 2

Alcohol-Related Liver Disease

• The American College of Gastroenterology recommends complete and permanent alcohol abstinence for all patients with alcoholic liver disease 1, 2
• The American College of Gastroenterology defines heavy drinking as >4 drinks/day or >14 drinks/week in men, and >3 drinks/day or >7 drinks/week in women—these thresholds must not be exceeded 2

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NAFLD)

• The European Association for the Study of the Liver recommends lifestyle modification as the primary treatment for MASLD, with weight loss of 7-10% required to improve steatohepatitis and achieve fibrosis regression 3, 1, 4
• The European Association for the Study of the Liver suggests achieving 5% weight loss to improve steatosis alone; 7-10% weight loss is necessary for fibrosis regression 4
• The European Association for the Study of the Liver recommends creating a 500-1000 kcal/day deficit: typically 1,200-1,500 kcal/day for women and 1,500-1,800 kcal/day for men 4
• The European Association for the Study of the Liver advises that weight loss must be gradual at 500-1000g per week maximum, as rapid weight loss worsens liver disease 4
• The European Association for the Study of the Liver recommends implementing a Mediterranean diet pattern with daily vegetables, fruits, fiber-rich cereals, nuts, fish or white meat, and olive oil—this reduces liver fat even without weight loss 3, 4
• The European Association for the Study of the Liver suggests eliminating fructose-containing beverages and processed foods 4
• The European Association for the Study of the Liver recommends replacing saturated fats with monounsaturated and polyunsaturated fats, especially omega-3 fatty acids 4
• The European Association for the Study of the Liver advises prescribing 150-300 minutes of moderate-intensity aerobic exercise per week or 75-150 minutes of vigorous-intensity exercise 3, 4
• The European Association for the Study of the Liver states that both aerobic and resistance training reduce liver fat, with vigorous exercise providing greater benefit for NASH and fibrosis than moderate exercise 4
• The European Association for the Study of the Liver recommends considering resmetirom if locally approved for non-cirrhotic MASH with significant fibrosis (stage ≥2), which demonstrates histological effectiveness on steatohepatitis and fibrosis 3
• The European Association for the Study of the Liver suggests using incretin-based therapies (semaglutide, tirzepatide) for patients with type 2 diabetes or obesity when indicated 3
• The European Association for the Study of the Liver recommends using GLP-1 agonists for NASH recovery; avoiding sulfonylureas and insulin as they may increase HCC risk 4
• The European Association for the Study of the Liver states that bariatric surgery is an option for patients with MASLD and obesity meeting national eligibility criteria—it resolves NASH in 85% of patients at 1 year and improves steatosis, steatohepatitis, and fibrosis 3, 4

Risk Stratification and Surveillance

• The American Association for the Study of Liver Diseases recommends using a stepwise approach with FIB-4 score followed by transient elastography to identify patients with advanced fibrosis who require closer monitoring 3
• The American Association for the Study of Liver Diseases suggests applying case-finding strategies in individuals with cardiometabolic risk factors, abnormal liver enzymes, and/or radiological hepatic steatosis, particularly with type 2 diabetes or obesity with additional metabolic risk factors 3
• The American Association for the Study of Liver Diseases recommends managing low-risk patients in the community with lifestyle advice and cardiovascular risk reduction, reassessing with non-invasive tests after 3 years 5
• The American Association for the Study of Liver Diseases states that fibrosis progresses in a significant proportion of individuals, so repeated assessment every 1-3 years is required in at-risk patients 5
• The American Association for the Study of Liver Diseases recommends performing 6-monthly ultrasound and AFP measurement for all cirrhotic patients 2
• The American Association for the Study of Liver Diseases advises that lifelong HCC surveillance is required for cirrhotic patients, even after viral clearance 1
• The American Association for the Study of Liver Diseases states that early treatment of underlying liver diseases before progression to cirrhosis is the most effective approach for preventing HCC and liver-related mortality 1

Vaccination and Prevention

• The Centers for Disease Control and Prevention recommends vaccinating against hepatitis B: all infants (universal childhood immunization), high-risk adults, and exposed individuals 2
• The Centers for Disease Control and Prevention suggests vaccinating against hepatitis A: all anti-HAV negative patients with chronic liver disease 2
• The Centers for Disease Control and Prevention states that hepatitis B vaccination reduces HCC risk and is recommended for all newborns and high-risk groups 1

Management of Cardiometabolic Comorbidities

• The American Heart Association recommends using statins for dyslipidemia in all NAFLD patients—they carry no increased risk of serious liver injury and reduce HCC risk by 37% 4
• The American Diabetes Association suggests optimizing treatment for type 2 diabetes, as patients with or who develop T2DM have higher risk of fibrosis progression 5
• The American Heart Association recommends assessing lipid profile, fasting glucose/HbA1c, waist circumference, and BMI regularly 4

Nut